Rigvir

Executive Summary

Rigvir Group is a private organization based in Riga, Europe, specializing in oncolytic virotherapy. Founded in 2018 but with roots dating back to 2002, the company focuses on developing the ECHO-7 virus, a unique oncolytic virus designed to selectively infect and destroy cancer cells while stimulating an anti-tumor immune response. Rigvir operates as a vertically integrated entity involved in research, development, and production of its viral therapy platform. With limited public financial details, the company remains pre-clinical, having not yet advanced to human trials. Its technology, based on an enterovirus, aims to address solid tumors and represents a differentiated approach in the competitive oncolytic virus landscape. Given its pre-clinical stage, Rigvir faces significant technical and regulatory hurdles before reaching the market. The oncolytic virotherapy field has seen progress with approvals like T-VEC, but ECHO-7's distinct mechanism and lack of clinical data create uncertainty. The company's private status and absence of disclosed partnerships or funding suggest early development. However, if Rigvir successfully demonstrates safety and efficacy in preclinical models, it could attract partnering interest or investment to advance into clinical trials. The upcoming catalysts—such as IND-enabling studies or initial clinical trial applications—will be critical for validating its platform and determining its future viability. Overall, Rigvir is a high-risk, early-stage biotechnology play with potential upside if the ECHO-7 virus proves effective.

Upcoming Catalysts (preview)

• Q3 2026Initiation of IND-Enabling Studies30% success
• TBDAnnouncement of Strategic Partnership or Licensing Deal20% success
• Q4 2026Presentation of Preclinical Efficacy Data at Major Conference40% success